TOP TEN perturbations for 38424_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38424_at
Selected probe(set): 208858_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38424_at (208858_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample
Relative Expression (log2-ratio):-2.930581Number of Samples:8 / 8
| Experimental | PMA; ionomycine study 2 |
| CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:--- | |
| Control | unstimulated CD4 memory T-cell sample |
| Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects. |
HCT 116 DICER1(-/-) / p53HCT116
Relative Expression (log2-ratio):2.7282915Number of Samples:3 / 3
| Experimental | HCT 116 DICER1(-/-) |
| Human primary cancer cell line derived from the colon of a patient with carcinoma. The cells have knockout DICER gene in exon 5 by using an AAV targeting construct. Parental cell line:: HCT 116 Synonyms:DICER1 (-/-) HCT116; HCT116 DICEREX5/EX5, DICERex5 Cellosaurus code: | |
| Control | p53HCT116 |
| Human primary cancer cell line derived from the colon of a patient with carcinoma. The cells have knockout gene for p53. Parental cell line:: HCT 116 Synonyms:P53HCT116; p53-/- HCT116; p53(-/-) HCT-116; HCT116-p53-/-; HCT116-p53 Cellosaurus code: |
phenobarbital study 3 (10000uM) / vehicle (medium) treated hepatocyte sample
Relative Expression (log2-ratio):-2.72748Number of Samples:2 / 2
| Experimental | phenobarbital study 3 (10000uM) |
| Hepatocytes treated with compound: phenobarbital (10000uM; CHEMBL40) for 24 hours. ATC code: | |
| Control | vehicle (medium) treated hepatocyte sample |
| Hepatocytes treated with vehicle (medium) for 24 hours. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-2.6980782Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):2.6238098Number of Samples:4 / 4
| Experimental | B-CLL study 11 (DMSO) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
| Control | vehicle (DMSO) treated normal B-cell sample |
| MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
p53HCT116 / HCT 116
Relative Expression (log2-ratio):-2.5622149Number of Samples:3 / 3
| Experimental | p53HCT116 |
| Human primary cancer cell line derived from the colon of a patient with carcinoma. The cells have knockout gene for p53. Parental cell line:: HCT 116 Synonyms:P53HCT116; p53-/- HCT116; p53(-/-) HCT-116; HCT116-p53-/-; HCT116-p53 Cellosaurus code: | |
| Control | HCT 116 |
| Human primary cancer cell line derived from the colon of a patient with carcinoma. Synonyms:HCT-116; HCT.116; HCT116 Cellosaurus code: |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):2.4072962Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
T-cell isolation study 11 / T-cell isolation study 6
Relative Expression (log2-ratio):-2.1958456Number of Samples:2 / 2
| Experimental | T-cell isolation study 11 |
| CD4+ resting memory T-cell were isolated from peripheral blood buffy coat of healthy donors after storage for 24 hours at 20°C. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population. | |
| Control | T-cell isolation study 6 |
| CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population. |
septic shock study 3 (D1; survivor) / normal blood sample
Relative Expression (log2-ratio):-2.1572456Number of Samples:34 / 22
| Experimental | septic shock study 3 (D1; survivor) |
| Blood samples from patients (survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
| Control | normal blood sample |
| Blood samples from healthy subjects. |
septic shock study 3 (D1; non-survivor) / normal blood sample
Relative Expression (log2-ratio):-2.1406755Number of Samples:17 / 22
| Experimental | septic shock study 3 (D1; non-survivor) |
| Blood samples from patients (non-survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
| Control | normal blood sample |
| Blood samples from healthy subjects. |